

# Interleukin-6 gene –174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population

## *Polimorfizmy –174 C/G genu interleukiny 6 oraz genu apolipoproteiny E a ryzyko rozwoju choroby Alzheimera w populacji polskiej*

Aleksandra Klimkowicz-Mrowiec<sup>1</sup>, Paweł Wołkow<sup>2</sup>, Karolina Spisak<sup>1</sup>, Aleksandra Maruszak<sup>3</sup>, Maria Styczyńska<sup>3</sup>, Maria Barcikowska<sup>3</sup>, Andrzej Szczudlik<sup>4</sup>, Agnieszka Słowik<sup>4</sup>

<sup>1</sup>Department of Neurology, University Hospital, Krakow, Poland

<sup>2</sup>Department of Pharmacology, Jagiellonian University Medical College, Krakow, Poland

<sup>3</sup>Department of Neurodegenerative Disorders, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

<sup>4</sup>Department of Neurology, Jagiellonian University Medical College, Krakow, Poland

Neurologia i Neurochirurgia Polska 2010; 44, 6: 537–541

### Abstract

**Background and purpose:** Inflammation plays a prominent role in Alzheimer disease (AD) pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine, and some genetic variations in the IL-6 gene have been reported to be associated with a risk of AD. However, the results of the conducted studies are equivocal.

**Material and methods:** We genotyped IL-6 (–174 C/G) and apolipoprotein E gene (APOE) common polymorphisms in a large case-controlled study in a Polish population. We included 361 patients aged  $\geq 65$  years with AD (mean age  $75.8 \pm 5.3$  years, 232 females [64.3%]) and 200 controls ( $75.3 \pm 7.4$  years; 119 females [59.5%]), without any neurological deficit, cognitive complaints or history of neurological diseases. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA).

**Results:** The distribution of the IL-6 (–174 C/G) genotypes was similar to that in the controls (AD: C/C = 15.79%, C/G = 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%, C/G = 45.50%, G/G = 33.0%,  $p > 0.05$ ). Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01–9.49). APOE status

### Streszczenie

**Wstęp i cel pracy:** Choroba Alzheimera jest najczęstszą chorobą zwyrodnieniową ośrodkowego układu nerwowego. Patogeneza choroby nie została poznana; uważa się, że procesy zapalne odgrywają istotną rolę w jej rozwoju. Interleukinę 6 (IL-6), będącą cytokiną prozapalną, oraz niektóre polimorfizmy genu IL-6 wiąże się ze wzrostem ryzyka zachorowania na chorobę Alzheimera, jednak wyniki badań nad tym zagadnieniem nie są jednoznaczne.

**Materiał i metody:** Do badania włączono 361 chorych  $\geq 65$ . roku życia [średnia wieku  $75,8 \pm 5,3$  roku, 232 kobiety (64,3%)] oraz 200 osób z grupy kontrolnej [ $75,3 \pm 7,4$  roku; 119 kobiet (59,5%)] bez skarg na zaburzenia funkcji poznawczych, chorób neurologicznych w wywiadzie i deficytu neurologicznego w badaniu klinicznym. Osoby chore i zdrowe były rasy kaukaskiej. Oznaczono polimorfizm IL-6 (–174 C/G) oraz apolipoproteiny E (APOE). Polimorfizm pojedynczego nukleotydu –174 C/G genu IL-6 został oznaczony za pomocą sond TaqMan na urządzeniu ABI 7900HT (Applied Biosystems, Foster City, CA).

**Wyniki:** Rozkład genotypu IL-6 (–174 C/G) u osób z chorobą Alzheimera i w grupie kontrolnej był podobny (choroba Alzheimera: C/C = 15,79%, C/G = 51,25%, G/G = 32,96%;

Correspondence address: Aleksandra Klimkowicz-Mrowiec, Department of Neurology, Jagiellonian University, ul. Botaniczna 3, 31-503 Krakow, phone: +48 12 424 86 00, fax: +48 12 424 8626, e mail: Aleksandra.Klimkowicz@mp.pl

Received: 14.07.2010; accepted: 15.09.2010

did not affect the distribution of the studied IL-6 polymorphism.

**Conclusion:** IL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.

**Key words:** Alzheimer disease, interleukin-6, APOE, polymorphism, risk factor, Polish population.

grupa kontrolna: C/C = 21,50%, C/G = 45,50%, G/G = 33,0%,  $p > 0,05$ ). Badanie potwierdziło, że APOE 4 jest czynnikiem ryzyka choroby Alzheimera (OR = 6,17; 95% CI: 4,01–9,49). Polimorfizm APOE nie miał wpływu na rozkład polimorfizmu IL-6.

**Wniosek:** Polimorfizm IL-6 (–174 C/G) nie jest czynnikiem ryzyka choroby Alzheimera o późnym początku w populacji polskiej.

**Słowa kluczowe:** choroba Alzheimera, interleukina 6, APOE, polimorfizm, czynniki ryzyka, populacja polska.

## Introduction

Alzheimer disease (AD) is the most common neurodegenerative disease. The main pathological feature of AD is the presence of abnormally accumulated proteins and loss of neurons in specific brain regions [1]. The progressive neurodegenerative process in AD is accompanied by chronic inflammation, including activation of microglia and astrocytes that express pro-inflammatory cytokines [2].

Several lines of evidence point to the involvement of interleukin-6 (IL-6) in pathogenesis of AD. Both experimental and clinical data indicate that brain expression [3–6], plasma [7–11] and cerebrospinal fluid levels [12] of IL-6 may affect plaque formation, cognitive decline or dementia both in cross-sectional and longitudinal follow-up studies.

The IL-6 gene in humans is located on chromosome 7 (7p21). The (–174 C/G) polymorphism in the promoter region of the IL-6 gene was reported to affect the IL-6 gene transcription rates [13] and IL-6 plasma levels in AD patients [13,14], implicating its role in development of AD.

Studies analysing a link between the IL-6 (–174 C/G) polymorphism and risk of AD in different ethnic groups have yielded conflicting results; some found an association [15–19] whereas others did not [14,20–28]. The aim of the present study was to investigate a possible association between the IL-6 (–174 C/G) polymorphism and the risk of AD in a case-control study in a large Polish population sample.

## Material and methods

### Participants

We studied a total sample of 561 subjects. The AD group consisted of 361 patients who were at least

65 years old at the onset of the disease (mean age,  $75.8 \pm 5.3$  years, 232 females [64.3%]) and had no family history of AD. Onset was defined as age at which memory loss or change in behaviour was first noted. The patients were recruited from the Outpatient Memory Clinic, Neurology Department, University Hospital in Krakow (58.5%) and the Department of Neurodegenerative Disorders, Medical Research Centre, Polish Academy of Sciences in Warsaw. Clinical diagnosis of probable AD was made according to the National Institute for Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria [29]. The evaluation included medical, neurological and neuropsychological examination, interview with a close informant, laboratory testing and computed tomography or magnetic resonance imaging. The details of patients' evaluation are described comprehensively elsewhere [30].

The control group included 200 unrelated caregivers or volunteers (mean age:  $75.3 \pm 7.4$  years; 119 females [59.5%]), consecutively recruited from the population of Krakow. They had no apparent neurological disease or psychiatric syndrome, cerebrovascular disease or severe functional limitations and obtained  $> 26$  points on the Mini-Mental State Examination (MMSE) [31]. Controls and AD patients were Caucasian and of Eastern European descent.

All participants gave informed consent and the study was approved by the Local Ethical Committee.

### Genetic analyses

The IL-6 promoter (–174 C/G) and the APOE common polymorphism were studied. DNA was extracted from leucocytes using the standard protocol. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA). The APOE

polymorphisms were genotyped by a PCR-based assay simultaneously utilizing two distinct restriction enzymes (HaeII and AflIII enzymes were applied).

## Statistical analyses

The genotype and allele frequencies of the IL-6 polymorphism were compared between cases and controls using the  $\chi^2$  test (SPSS for Windows, v.10.0). The Hardy-Weinberg equilibrium was verified for all tested populations. Adjusted odds ratios (OR) with 95% confidence intervals (CI) were estimated by logistic regression, controlling for APOE 4 carrier status, gender, and age. The level of significance was set at  $p < 0.05$ .

To achieve 80% power in this study, with 361 cases and 200 controls, at 0.05 alpha error the effect of the IL-6 allele would have to be  $OR > 1.44$ .

The results of our study were combined with those of the previous studies assessing the significance of the studied polymorphism using a fixed or random effect model with the software MIX version 1.7.

## Results

Genotype distributions of the IL-6 (-174 C/G) polymorphism and the APOE gene common polymor-

phism in both groups were in Hardy-Weinberg equilibrium. The frequencies of the G/G genotype and the G allele were similar in AD patients and controls and the difference did not reach significance ( $p = 0.20$  and  $0.30$ , respectively). Table 1 shows the IL-6 genotype and allele distribution in patients and controls.

The genotype with the APOE 4 allele was found in 54.2% of the studied patients and in 16.0% of the controls ( $p < 0.001$ ). The possession of at least one E4 allele was associated with a risk of AD in univariate analysis ( $OR = 6.16$ , 95% CI: 4.01-9.49,  $p < 0.0001$ ) and after adjustment for gender and age at disease onset ( $OR = 6.17$ , 95% CI: 4.01-9.50,  $p < 0.0001$ ). We examined the distribution of the IL-6 genotype and allele frequencies after stratification of the data by APOE 4 carrier status. We found that the distribution of the studied polymorphism did not differ between the carriers and non-carriers of the APOE 4 allele (Table 1).

After pooling the results of our study with the results of the 14 previous studies in Caucasians available in the AlzGene database (<http://www.alzgene.org/meta.asp?geneID=53>) we found that the studied polymorphism did not affect the risk of developing AD when the significance of the C vs. T allele was considered ( $OR = 1.0012$ ; 95% CI: 0.9355-1.0714,  $z$ -statistic = 0.0334,  $p = 0.97$ ).

**Table 1.** IL-6 (-174 C/G) and APOE ( $\epsilon$ 2/3/4) genotype and allele frequencies for patients with Alzheimer disease (AD) and controls

IL-6 (-174 C/G) genotypes	AD patients (N = 361)	Controls (N = 200)	$\chi^2$ – statistic value	p-value
CC	57 (15.80%)	43 (21.50%)	3.21 (df = 2)	0.20
GC	185 (51.25%)	91 (45.50%)		
GG	119 (32.96%)	66 (33.0%)		
IL-6 (-174 C/G) allele				
C	299 (41.41%)	177 (44.25%)	0.84 (df = 1)	0.30
G	423 (58.59%)	223 (55.75%)		
APOE ( $\epsilon$ 2/3/4) genotypes				
2/2	0 (0%)	2 (1.0%)	89.25 (df = 5)	< 0.0001*
2/3	19 (5.26%)	24 (12.00%)		
3/3	147 (40.72%)	142 (71.00%)		
2/4	8 (2.22%)	7 (3.50%)	77.21 (df = 1)	< 0.0001
3/4	162 (44.88%)	25 (12.50%)		
4/4	25 (6.93%)	0 (0%)		
2/2 or 2/3 or 3/3	166 (45.98%)	168 (81.0%)	77.21 (df = 1)	< 0.0001
2/4 or 3/4 or 4/4	195 (54.02%)	32 (19.0%)		

\*Cochran-Armitage Trend Test;  $Z = -7.99$

## Discussion

We did not find any evidence of an association between the IL-6 (–174 C/G) polymorphism and late onset AD in the Polish population sample. The distribution of the studied polymorphism was similar to that observed in countries at the same geographic latitude, but different when geographical longitude was considered [14]. Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01-9.49) [32,33]. APOE status did not affect the distribution of the studied IL-6 polymorphism.

Previous studies (12 case-control and 2 prospective studies) assessing the connection between the IL-6 polymorphism and the risk of AD brought equivocal results. Faltraco *et al.* [16] reported risk reducing association of the IL-6 C allele in AD. Pola *et al.* [18] found that the G/G polymorphism was associated with increased risk of AD. In other studies on Italian populations the IL-6 C allele increased the risk of AD [12,14], the C/C genotype increased the risk of AD in women [17], and the G/G genotype was lower in AD than in healthy controls [15]. However, other studies did not find an association between the IL-6 polymorphism and AD [14, 20-28].

Differences in study design and the geographical variations of IL-6 frequency may in part explain the different patterns of association between this polymorphism and AD in various studies. In most studies patients with AD had neuropsychological examination but in controls no test battery was used, apart from MMSE; therefore some cases with incipient AD might have been included. Moreover, all studies published to date analysing the role of the IL-6 (–174 C/G) polymorphism in AD have been underpowered. That is why we performed a meta-analysis assessing the significance of the studied polymorphism on all available data from 3107 AD patients and 10 014 controls. This meta-analysis, however, was not able to show the significance of the IL-6 (–174 C/G) polymorphism for the risk of AD.

## Conclusion

IL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.

## Acknowledgement

This research was supported by grant K/ZDS/001021 from Jagiellonian University.

## Disclosure

The authors report no conflict of interest.

## References

- Sheng J.G., Griffin W.S., Royston M.C., et al. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease. *Neuropathol Appl Neurobiol* 1998; 24: 278-283.
- Rogers J., Webster S., Lue L.F., et al. Inflammation and Alzheimer's disease pathogenesis. *Neurobiol Aging* 1996; 17: 681-686.
- Hüll M., Berger M., Volk B., et al. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. *Ann N Y Acad Sci* 1996; 17: 205-212.
- Bauer J., Strauss S., Schreiter-Gasser U., et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. *FEBS Lett* 1991; 8: 111-114.
- Hampel H., Haslinger A., Scheloske M., et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. *Eur Arch Psychiatry Clin Neurosci* 2005; 255: 269-278.
- Luterman J.D., Haroutunian V., Yemul S., et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. *Arch Neurol* 2000; 57: 1153-1160.
- Weaver J.D., Huang M.H., Albert M., et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. *Neurology* 2002; 13: 371-378.
- Engelhart M.J., Geerlings M.I., Meijer J., et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. *Arch Neurol* 2004; 61: 668-672.
- Baranowska-Bik A., Bik W., Wolinska-Witort E., et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. *Neuro Endocrinol Lett* 2008; 29: 75-79.
- Bermejo P., Martín-Aragón S., Benedí J., et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. *Immunol Lett* 2008; 15: 198-202.
- Licastro F., Pedrini S., Caputo L., et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? *J Neuroimmunol* 2000; 1: 97-102.
- Blum-Degen D., Müller T., Kuhn W., et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. *Neurosci Lett* 1995; 202: 17-20.
- Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest* 1998; 102: 1369-1376.
- Capurso C., Solfrizzi V., D'Introno A., et al. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. *Exp Gerontol* 2004; 39: 1567-1573.

15. Arosio B., Trabattoni D., Galimberti L., et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. *Neurobiol Aging* 2004; 25: 1009-1015.
16. Faltraco F., Bürger K., Zill P., et al. Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. *J Am Geriatr Soc* 2003; 51: 578-579.
17. Licastro F., Grimaldi L.M., Bonafè M., et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. *Neurobiol Aging* 2003; 24: 921-926.
18. Pola R., Flex A., Gaetani E., et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with Alzheimer's disease in an Italian population [corrected]. *Neuroreport* 2002; 16: 1645-1647.
19. Shibata N., Ohnuma T., Takahashi T., et al. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. *Am J Med Genet* 2002; 8: 436-439.
20. Koivisto A.M., Helisalmi S., Pihlajamäki J., et al. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. *J Neurogenet* 2005; 19: 155-161.
21. Zhang Y., Hayes A., Pritchard A., et al. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. *Neurosci Lett* 2004; 20: 99-102.
22. Bhojak T.J., DeKosky S.T., Ganguli M., et al. Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer's disease. *Neurosci Lett* 2000; 7: 21-24.
23. Depboylu C., Lohmüller F., Gocke P., et al. An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. *Dement Geriatr Cogn Disord* 2004; 17: 170-173.
24. Paradowski B., Celczyńska D., Dobosz T., et al. Polymorphism 174 G/C of interleukin 6 gene in Alzheimer's disease – preliminary report. *Neurol Neurochir Pol* 2008; 42: 312-315.
25. Bagli M., Papassotiropoulos A., Knapp M., et al. Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population. *Neurosci Lett* 2000; 7: 109-112.
26. van Oijen M., Hofman A., Soares H.D., et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. *Lancet Neurol* 2006; 5: 655-660.
27. Ravaglia G., Paola F., Maioli F., et al. Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. *Exp Gerontol* 2006; 41: 85-92.
28. Capurso C., Solfrizzi V., Colacicco A.M., et al. Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 1: 177-182.
29. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer's disease. *Neurology* 1984; 34: 939-944.
30. Klimkowicz-Mrowiec A., Slowik A., Krzywoszański L., et al. Severity of explicit memory impairment due to Alzheimer's disease improves effectiveness of implicit learning. *J Neurol* 2008; 20: 234-240.
31. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189-198.
32. Poirier J., Davignon J., Bouthillier D., et al. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet* 1993; 18: 697-699.
33. Brousseau T., Legrain S., Berr C., et al. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. *Neurology* 1994; 44: 342-344.